Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Common Equity (2021 - 2026)

bioAffinity Technologies has reported Common Equity over the past 6 years, most recently at $3.7 million for Q1 2026.

  • Quarterly Common Equity rose 154.37% to $3.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Mar 2026, up 154.37% year-over-year, with the annual reading at $7.3 million for FY2025, 179.69% up from the prior year.
  • Common Equity was $3.7 million for Q1 2026 at bioAffinity Technologies, down from $7.3 million in the prior quarter.
  • Over five years, Common Equity peaked at $12.6 million in Q3 2022 and troughed at -$16.8 million in Q2 2022.
  • The 5-year median for Common Equity is $4.9 million (2023), against an average of $3.1 million.
  • The largest YoY upside for Common Equity was 185.23% in 2025 against a maximum downside of 162.22% in 2025.
  • A 5-year view of Common Equity shows it stood at $11.0 million in 2022, then tumbled by 56.03% to $4.9 million in 2023, then tumbled by 46.41% to $2.6 million in 2024, then soared by 179.69% to $7.3 million in 2025, then crashed by 49.69% to $3.7 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Common Equity are $3.7 million (Q1 2026), $7.3 million (Q4 2025), and $8.9 million (Q3 2025).